Sort
48,018 grants matching “immunotherapy”
Adoptive Cellular Gene Therapy in Type 1 Diabetes (T1D)
$392,500Stanford University · R33 · FY2004 · AI
Engineering Anti-Tau Intrabodies that Reduce Tauopathy by Either the Proteasome, Lysosome, or Chaperone Mediated Autophagy
$392,500Gilbert Gallardo · Washington University · R01 · FY2019 · AG
Effects of IgE Blockade on T Cells in Food Allergy
$392,500Kari C. Nadeau · Stanford University · R01 · FY2020 · AI
Effects of IgE Blockade on T Cells in Food Allergy
$392,500Kari C. Nadeau · Stanford University · R01 · FY2021 · AI
Particulate-based in vivo modulation for immunotherapy of Rheumatoid Arthritis
$392,500Jamal S Lewis · University Of California At Davis · R01 · FY2021 · AI
Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma
$392,485Athan Kuliopulos · Oasis Pharmaceuticals · R41 · FY2022 · CA
Off-the-shelf iPSC-Derived Natural Killer Cell Immunotherapies for AML
$392,480Jeffrey S Miller · University Of Minnesota · P01 · FY2025 · CA
Role of TRIF-dependent TLR signaling in intestinal immunity
$392,450Masayuki Fukata · Cedars-Sinai Medical Center · R01 · FY2013 · AI
Reprogramming the Tumor Microenvironment in Ovarian Cancer
$392,449David D Schlaepfer · University Of California, San Diego · R01 · FY2024 · CA
Pharmacologic Enhancement of Viral Oncolysis
$392,403E. Antonio Chiocca · Massachusetts General Hospital · P01 · FY2008 · CA
A Novel Symbiotic Approach For Targeted Ovarian Cancer Therapy
$392,353Jogender Tushir-Singh · University Of Virginia · R01 · FY2020 · CA
Biased chemokine receptor signaling in cancer progression
$392,318Michael B Dwinell · Medical College Of Wisconsin · R01 · FY2021 · CA
Intestinal Cytokines in Cryptosporidiosis
$392,268Baylor College Of Medicine · R01 · FY2003 · AI
Development of a New Strategy to Treat Locally Advanced Pancreatic Cancer
$392,242Scott Andrew Gerber · University Of Rochester · R01 · FY2023 · CA
Development of a New Strategy to Treat Locally Advanced Pancreatic Cancer
$392,238Scott Andrew Gerber · University Of Rochester · R01 · FY2022 · CA
Project 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancer
$392,202Panagiotis Konstantinopoulos · Dana-Farber Cancer Inst · P50 · FY2024 · CA
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
$392,171Mark W Jackson · Case Western Reserve University · R01 · FY2024 · CA
Project 1: Siglec15 as a new target for lung cancer immunotherapy
$392,133David L Rimm · Yale University · P50 · FY2023 · CA
Stromal metabolism promotes therapeutic resistance in pancreatic cancer
$392,124Costas Andreas Lyssiotis · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Monitoring neurochemical signaling dynamics in the lymph node
$392,085Ashley E Ross · University Of Cincinnati · R01 · FY2024 · AI
Pathogenesis of Postoperative Cognitive Dysfunction
$392,083Zhongcong Xie · Massachusetts General Hospital · R01 · FY2017 · AG
Elucidating the Roles of RNA m6A readers Y1 and Y2 in radiation-induced immunity and immunotherapy
$392,077Ralph R Weichselbaum · University Of Chicago · R01 · FY2024 · CA
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
$392,015Zachary Scott Morris · University Of Wisconsin-Madison · P01 · FY2021 · CA
THE UTSW RESEARCH PROJECT WILL INVESTIGATE IMMUNOGLOBULIN E (IGE) GLYCOSYLATION TO REPLACE THE ORAL FOOD CHALLENGE TEST. IGE CUT-OFF LEVELS ARE UNCLEAR (CAN BE FALSELY POSITIVE) AND WHILE IMMUNOTHERAPY RESPONDERS DECREASE THEIR IGE, SIGE DOES NOT RELIABLY PREDICT RESPONSE, SO FOOD CHALLENGES MUST BE PERFORMED. RECENT WORK HAS DEMONSTRATED POST-TRANSLATIONAL MODIFICATIONS IN THE FORM OF GLYCOSYLATION REGULATES THE ANAPHYLACTIC POTENTIAL OF IGE AND COULD EXPLAIN THIS DISCONNECT. HOWEVER, THIS OBSERVATION WARRANTS DEEPER INVESTIGATION AND CLINICAL VALIDATION IN A FOOD ALLERGY TRIAL TO DETERMINE IF IGE GLYCOSYLATION CAN PREDICT ALLERGIC REACTIVITY. THIS GOAL WILL BE PURSUED BY JEFF SORELLE MD, A PHYSICIAN SCIENTIST (PI), WHOSE BASIC SCIENCE RESEARCH OF IGE HAS LED HIM TO STUDY THE IMPACT OF IGE GLYCOSYLATION ON ALLERGIES. HIS MEDICAL TRAINING IS IN VALIDATING CLINICAL DIAGNOSTICS AND HAS ASSEMBLED A TEAM EXPERIENCED IN THROUGH THE FOLLOWING AIMS: AIM 1: ANALYTICALLY VALIDATE AN IGE GLYCAN TEST (BY MASS-SPEC OR ALTERNATIVE METHOD), AIM 2: ESTABLISH IGE-GLYCOSYLATION CUT-OFF FOR ALLERGIC REACTIVITY, AND CLINICALLY VALIDATE IGE-GLYCOSYLATION AS A BIOMARKER ON A BROADLY REPRESENTATIVE POPULATIONFROM COHORTS TREATED WITH PEANUT ORAL IMMUNOTHERAPY OR CONTROL COHORTS WITHOUT PEANUT ALLERGY.
$392,000The University Of Texas Southwestern Medical Center · · FY2025 · National Institute of Food and Agriculture
Immunologic basis of phenotypic heterogeneity in peanut allergy
$391,986Maria Cecilia Berin · Icahn School Of Medicine At Mount Sinai · U19 · FY2020 · AI